Shots:

• AstraZeneca reported long-term follow-up from the positive P-ll ACE-LY-004 study involves assessing Calquence (acalabrutinib) in adult patients with r/r MCL
• Result: @median follow up (38.1mos.) 44% of patients either remained on treatment or continued to be followed for survival; median DOR (28.6 mos.); estimated DOR rate @36 mos. (41.9%); m-PFS (22 mos.); estimated PFS rate @6mos. (37.2%); presented at ASH
• Calquence is a selective BTK inhibitor- binds BTK thereby inhibiting its activity- and is approved for CLL and SLL in the US and for CLL in the EU and several other countries globally

 ­ Ref: Businesswire | Image: Royal Haskoning